Pleomorphic Rhabdomyosarcoma — Trials

Pleomorphic Rhabdomyosarcoma — Trials · CancerIndex

Clinical trials

Registered studies

11 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 5
Recruiting: 3
Ph III recruiting: 0
Growth YoY: —
Industry share: 20%
Top sponsor: Oslo University Hospital
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02050919	Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma	completed	Phase 2	20	OHSU Knight Cancer InstituteOTHER	1	Mar 21, 2022	clinicaltrials
NCT01222715	Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma	completed	Phase 2	87	National Cancer Institute (NCI)NIH	4	May 5, 2017